Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Shares Shorted: Short Interest Down 53.4% in September

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totaling 9,250 shares, a decline of 53.4% from the September 15th total of 19,861 shares. Based on an average daily trading volume, of 6,232 shares, the short-interest ratio is presently 1.5 days. Approximately 0.0% of the shares of the company are short sold.

Ascentage Pharma Group International Price Performance

NASDAQ AAPG traded up $0.41 during trading hours on Tuesday, hitting $15.16. The company’s stock had a trading volume of 1,235 shares, compared to its average volume of 6,820. The stock has a fifty day moving average of $16.68 and a 200 day moving average of $19.27. Ascentage Pharma Group International has a twelve month low of $14.45 and a twelve month high of $37.50. The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The company had revenue of $22.24 million during the quarter. As a group, equities analysts predict that Ascentage Pharma Group International will post -2.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AAPG. Citigroup assumed coverage on Ascentage Pharma Group International in a research note on Tuesday. They issued an “outperform” rating on the stock. BTIG Research restated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. Citizens Jmp assumed coverage on Ascentage Pharma Group International in a research note on Tuesday. They issued a “market outperform” rating and a $35.00 price target on the stock. Finally, JPMorgan Chase & Co. decreased their price target on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research note on Thursday, October 8th. Two research analysts have rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the company. According to data from MarketBeat, Ascentage Pharma Group International currently has an average rating of “Buy” and a consensus price target of $43.67.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.